Moberg Pharma announces plans to develop BUPI through phase III
STOCKHOLM, March 22, 2015. Moberg Pharma AB (OMX: MOB) today announced a decision to initiate development of BUPI through phase III. The decision follows an evaluation of the complete data set from the recent phase II study for BUPI.BUPI is a patent pending lozenge formulation of bupivacaine for pain management in oral mucositis in cancer patients. Following positive phase II results, the board has approved a de-risked strategy to continue development through phase III, including one phase III trial to be conducted in Europe co-funded by a grant from Eurostars. A second phase III study will